A detailed history of Baader Bank Aktiengesellschaft transactions in Bio N Tech Se stock. As of the latest transaction made, Baader Bank Aktiengesellschaft holds 144,281 shares of BNTX stock, worth $14.9 Million. This represents 1.05% of its overall portfolio holdings.

Number of Shares
144,281
Previous 140,750 2.51%
Holding current value
$14.9 Million
Previous $11.3 Million 51.51%
% of portfolio
1.05%
Previous 0.75%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$78.36 - $124.66 $276,689 - $440,174
3,531 Added 2.51%
144,281 $17.1 Million
Q2 2024

Jul 17, 2024

BUY
$80.36 - $102.87 $454,034 - $581,215
5,650 Added 4.18%
140,750 $11.3 Million
Q1 2024

May 03, 2024

SELL
$88.96 - $112.35 $191,975 - $242,451
-2,158 Reduced 1.57%
135,100 $12.5 Million
Q4 2023

Feb 08, 2024

BUY
$90.91 - $112.75 $196,820 - $244,103
2,165 Added 1.6%
137,258 $14.5 Million
Q3 2023

Nov 14, 2023

BUY
$98.5 - $125.08 $420,890 - $534,466
4,273 Added 3.27%
135,093 $14.7 Million
Q2 2023

Aug 11, 2023

SELL
$102.58 - $129.66 $11.8 Million - $14.9 Million
-115,270 Reduced 46.84%
130,820 $14.1 Million
Q1 2023

May 15, 2023

BUY
$122.57 - $153.67 $893,535 - $1.12 Million
7,290 Added 3.05%
246,090 $30.7 Million
Q4 2022

Feb 14, 2023

BUY
$118.43 - $186.05 $1.89 Million - $2.98 Million
16,000 Added 7.18%
238,800 $35.9 Million
Q3 2022

May 04, 2023

SELL
$127.65 - $183.11 $2.04 Million - $2.93 Million
-16,000 Reduced 6.7%
222,800 $30.1 Million
Q3 2022

Nov 14, 2022

SELL
$127.65 - $183.11 $255,300 - $366,220
-2,000 Reduced 0.89%
222,800 $30.1 Million
Q1 2022

May 18, 2022

BUY
$126.25 - $231.85 $8.54 Million - $15.7 Million
67,640 Added 43.04%
224,800 $38.3 Million
Q4 2021

May 17, 2022

BUY
$216.64 - $362.52 $34 Million - $57 Million
157,160 New
157,160 $40.5 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $25.1B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Baader Bank Aktiengesellschaft Portfolio

Follow Baader Bank Aktiengesellschaft and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baader Bank Aktiengesellschaft, based on Form 13F filings with the SEC.

News

Stay updated on Baader Bank Aktiengesellschaft with notifications on news.